HAYWARD, Calif., April 14, 2023 (GLOBE NEWSWIRE) — Predicine, a global molecular insights company, announced today that it is presenting data from 12 studies and launching PredicineALERT™, a next-generation liquid biopsy for minimal residual disease (MRD), will introduce assay at the AACR 2023 Conference, April 14-19, 2023. PredicineALERT™ offers a generalized approach to MRD testing – an assay without the need for personalized individual probe designs, but instead utilizing methylation profiles.
Key highlights of the PredicineALERT™ MRD Assay include:
- Tumor-naïve MRD detection without the need for personalization
- Fast turnaround time (TAT) of up to 6 days
- Sample input with only 2.5 ng of cell-free DNA
Predicine will also present twelve posters demonstrating the clinical utility and efficacy of Predicine’s liquid biopsy platform across a variety of indications, clinical trials and profiling applications.
A full list of Predicine posters:
| presentation plan | title | poster no | ||||
| Sunday April 16 | 1:30 p.m. – 5:00 p.m | ||||||
| • | Tissue-informed ctDNA MRD assay detects postoperative residual disease in HCC patients | 1020 | ||||
| • | Liquid biopsy-based comprehensive genomic profiling reveals the mutational landscape in advanced breast cancer | 1049 | ||||
| • | Development of a rapid, highly sensitive cell-free RNA-NGS assay to detect gene fusions and splice variants in cancer | 221 | ||||
| • | Development of a novel urine cell-free DNA preservation method for molecular profiling of urogenital tumors | 245 | ||||
| Monday April 17 | 9:00 a.m. – 12:30 p.m | ||||||
| • | Adverse clinical outcomes and differential genomic phenotype of BRCA-deficient metastatic castration-resistant prostate cancer | 2303 | ||||
| • | Comparative genomic profiling and disease surveillance in inoperable gastric and colon cancer | 2197 | ||||
| • | Long-term outcome and ctDNA correlatives for CAPOX BETR: A multicenter phase II study of capecitabine, oxaliplatin, bevacizumab and… | |||||
[ad_2]
Source story
